Company Performance - The S&P 500 has shown sluggish performance in early 2026, rising just over 1% overall, but several individual companies have significantly outperformed this benchmark [2] - Corvus Pharmaceuticals Inc. has seen its shares spike by 188% year-to-date, driven by positive trial data for its drug candidate soquelitinib, which showed a 72% reduction in eczema severity in a Phase 1 trial [3][4] - New Era Energy & Digital has made progress in providing data center capacity despite facing legal hurdles [6] - USA Rare Earth has secured approximately $1.6 billion in federal funding to develop a domestic alternative to foreign rare earth minerals [6] Investment Outlook - Analysts remain bullish on Corvus Pharmaceuticals, with six out of seven analysts rating the stock as a Buy and a consensus price target suggesting an additional 51% growth potential [5] - Corvus initiated a $150 million equity offering to fund its upcoming Phase 2 trial, which is crucial for maintaining its cash runway, as it ended Q3 2025 with only $67 million in cash reserves [4]